The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less

Waldenstrom macroglobulinemia (WM) is characterized by the production of serum monoclonal immunoglobulin (Ig) M and by lymphoplasmacytic bone marrow infiltration.[1][1] Upregulation of interleukin 6 (IL6) has been demonstrated in WM,[2][2],[3][3] in accordance with the increased IL6 serum